Fig. 2: BRCA2 mutated tumors are associated with mutations in an SBS5 context and response to chemotherapy.

a Number of mutations in an SBS5 context in relation to response to chemotherapy. b Mutation status of ERCC2 compared to chemotherapy response. c, d Volcano plots showing the difference between the median number of mutations for mutated tumors and the median number of mutations for wild-type tumors for all genes mutated in more than 5% of the patient cohort (only mutations with moderate- or high protein impact are considered). The red dashed lines indicate significance levels at p = 0.05. c Represents the number of mutations in an SBS5 context and d represents the number of mutations in an SBS2+13 (APOBEC) context. P-values were calculated using a permutation test (n = 100,000) that controls for mutation burden per sample and gene. e Mutation status of BRCA2 compared to chemotherapy response. f Kaplan–Meier survival analysis depicting the probability of overall survival stratified by BRCA2 mutation status. g–j Based on TCGA data. g Number of mutations in an SBS5 context for ERCC2 and BRCA2 wild-type and mutant samples in TCGA data. h Number of mutations in an SBS2+13 (APOBEC) context for ERCC2 and BRCA2 wild-type and mutant samples in TCGA data. i, j Mutation status of ERCC2 and BRCA2 compared to response to chemotherapy in TCGA data. P-values were calculated using a Fisher’s exact test for categorical variables, a Wilcoxon rank-sum test for continuous variables and a log-rank test for comparing survival curves. For all boxplots, the center line represents the median, box hinges represent first and third quartiles, whiskers represent ±1.5 × interquartile range (IQR) and points represent outliers. Source data are provided as a Source data file.